The Cytochrome P450 and GST System and Carcinogenesis
beingtwiceasinducibleasthem1mutant [81]
.Smokerswiththem2mutanthavemore DNAadductsintheirleucocytesthansmokerswithoutthismutant
[82] .Theseadductsare
alsoincreasedinthecordvenousbloodofneonateswithCYP1A1-MspIpolymorphism [82]
. B[a]PDE concentration and PAH-DNA adducts correlate positively with enzyme activity in the parenchymal lung tissue of smokers
[36] . Homozygous CYP1A1-MspI
allelesareobservedmorerarelyinCaucasiansthaninJapanese [83]
. AssociationswithCYP1A1activityhavebeendemonstratedinmorethan20studiesin
differentethnicpopulationsseeTable 5.3
.AccordingtostudiesfromJapan,thelungcan- cerriskwasdemonstratedwithbothm1andm2mutants
[85] .TheCYP1A1phenotypewas
importantintermsofthedevelopmentofSCCsonlyinmoderatesmokers [88]
.Theresults werenotcorroboratedinNorwegian,Finnish,SwedishandUSpopulations,aindingthat
waspossiblyattributabletothesmalleroccurrenceofthem1alleleinCaucasians.Studies conductedinamixedUSpopulationandinFrenchpatientsshowednoevidenceofapre-
ferredallelem1orm2forincreasedcancerprevalence.Inonestudy,individualswiththe m3mutationm1m1,m2hadanincreasedACriskwithanORof8.4
[97] ,whereasother
cancertypesdidnotoccurwithincreasedfrequencyTable 5.3
[30,97–100]
.Wherethe m1andm2variantsofCYP1A1occurredincombinationwiththeGSTM100genotype,
therewasanincreasedincidenceofSCCinJapanesesubjects [63,85,101]
.
CYP1A2: This enzyme activates numerous procarcinogens from tobacco, preferen-
tially aromatic and heterocyclic amines, and metabolises nicotine. The sequence of CYP1A2is72identicalwiththatofCYP1A1.However,itisformedprincipallyinthe
liverandtoaverymuchsmallerextentinthelungs [102]
.Theenzymeisofmarginal importanceforanincreasedriskoflungcancer.
CYP2D6:ThisenzymemetabolisesdebrisoquineandpoormetabolisersPMshavea
lesser risk for the development of lung cancer than extensive metabolisers EMs [71]
. However,theenzymealsoactivatesNNKandmetabolisesnicotine
[103] .Associationsevi-
dentlyexistbetweennicotinedependenceandmetaboliserstatus [104]
.Anincreasedlung cancerriskhasbeendemonstratedinEMs
[63,93,105–107] ,whereastwometa-analyses
haverejectedsuchanassociationonthebasisofthedatareviewed [22,107,108]
.
CYP2E1:CYP2E1,whichisinduciblebyethanolandnumerousotheragents,iscapa-
ble of metabolising NNK, NNN and other soluble nitrosamines from tobacco smoke. Structural enzyme variants are less important for an increased lung cancer risk in
Caucasians,withonly2outof11studiesshowingsuchainding [63,109,110]
.RsaIand DraIpolymorphismsofCYP2E1havenotbeenshowntocorrelatewiththedevelopment
ofSCC;wheretheseenzymevariantswerepresent,therewasatenfoldreductioninthe
Polymorphism Pointmutation
Systematicnomenclature forthemutation
Wildtypeallele,m1 None
wt MspIallele,3′,non-codingregion,m2
6,235T→C m1
Ile→Val,exon7,codon462 4,889A→G
m2 Afro-American-speciicallele,intron7
5,639T→C m3
Thr→Asn,exon7,codon461 4,887C→A
m4
Table 5.2
OverviewofCYP1A1subforms [79]
SCCsquamouscellcarcinoma;ACadenocarcinoma;SCLCsmallcelllungcancer;LCLClargecell lungcancer;LClungcancer,wtwildtype;PMpoormetaboliser;EMextensivemetaboliser;HEM
heterozygousextensivemetaboliser,m1tom4:seeTable 5.1
,CminorAllele;Dgeneralallele, DraI,RsaI:seetext
Gene, mutant
Cancer types
Cases controls
Genotype,frequency Signiicanceodds
ratio;95CI References
1A1m1 SCC,AC,
SCLC, LCLC
68104 m1m1:23.510.6;
wtwt:35.349.0 LC:3.1;SCC:4.6
[84] 1A1m2
SCC,AC 212358
m2m2:12.34.7; wtwt:56.7665.1
LC:2.971.59–5.57; SCC:3.34
1.49–7.52;AC: 2.541.48–4.34
[85] 1A1m1,m2
SCC 85170
m1m1:22.48.8; wtwt:38.848.2;
m2m2:10.63.5; wtwt:58.864.7
m1m1:sm+:6.55 2.49–17.24;
sm++:8.32 2.34–29.62;m2
m2:sm+:8.46 2.48–28.85;
sm++:8.46 1.68–42.73
[86]
1A1m1 SCC,AC,
SCLC, LCLC
267151 m1m1:16.910.6;
wtwt:36.744.3 m1m1undm1wt:
1.711.07–2.69 [87]
1A1m1–4 LC
157314 m3:00;m4:2.872.87
m2:3.011.29–7.26 [88]
1A1m1 AC,SCC
207283 m1m1:1.00.7;
m1wt:16.917.0; wtwt:82.182.3
m1wt+m1m1:LC 2.081.15–3.73;
ACsm+:2.25 1.13–4.48;m1
wt:LC1.15 1.0–2.3
[89]
1A1m2 SCC,
SCLC, AC
247185 m2m2:11.33.8;
m2wt:38.145.4; wtwt:50.650.8
m2m2:LC3.3 1.3–8.6;SCC4.9
1.4–16.3;SCLC 9.42.1–42.0
[90] 1A1m1,m2 SCC,AC,
SCLC, LCLC
10895 m1m1:22.210.5;
wtwt:36.1-; m2m2:16.76.3;
wtwt:53.7– m1m1:LC2.93
1.26–6.84. m2m2LC:3.45
1.29–9.25 [91]
1A1m1,m2 SCC, SCLC,
AC 8563
m1m1:75;wtwt:4046; m2m2:½;m2wt:
8095;wtwt:193 m2m2oderm2wt:
0.140.03–0.64 [92]
2D63, 4,5
SCC,AC 106122
PM:0.95.7;HEM+ EM:6.41.0–14.3
[93,94] EM:99.194.3
2E1DraI SCC,AC,
SCLC 4756
CC:010.7;CD:46.8 30.4;DD:53.259.9
p0.05 [95,96]
2E1DraI SCC,AC,
SCLC, LCLC
9176 CC:2.214.5;CD:46.2
28.9;51.656.6 CC:0.130.04–0.51
aberCD:2.1 1.1–4.0
[95,96] 2E1DraI,
RsaI SCC,AC,
SCLC 341456
DraI:CC1.55.5;CD: 27.526.8;DD71
67.7;RsaI:c2c20.6 3.1.c1c2:19.622.5;
c1c179.874.4 DraIalleleLC:CC0.2
0.1–0.7;AC:CC 0.10.0–0.5;
RsaI:c2c2:0.1 0.0–0.5
[63]
Table 5.3
CYPenzymes1A1,2D6and2E1andthedevelopmentoflungcancer
riskforSCLC,whilethedevelopmentofACwaspromotedbyCYP2E1mutants [63]
.In onefurtherstudy,thepresenceofap53mutationandac2c2genotypewasshowntocor-
relatefortheincreasedoccurrenceofSCCofthelung [111]
.
GSTSystem:AnunfavourablecombinationofCYP1A1withaGSTM100genepos-
siblyleadstosupra-additiveDNAdamageandtoanincreasedcancerriskbecausedetoxii- cationmaybedelayedasaresultofslowercouplingofcarcinogenstotheGSTsystem.
Moreover,damagedGSTM1activityisassociatedwithahighinducibilityofCYP1A1by 2,3,7,8-tetrachlorodibenzo-p-dioxin
[95] ,aphenomenonrelectedinthedetectedpresence
ofB[a]PDEadductsinthelungtissueofsmokersandencounteredprimarilyinCaucasians. High B[a]PDE-DNA adduct levels in lung tissue in Caucasians were associated with a
GSTM1phenotypedefectduetohighCYP1A1inducibilityorwithaCYP1A1allele [112,
113] .Thisconstellationleadstotobacco-inducedDNAdamageandtheincreasedoccur-
renceoflungcancer.AweakcorrelationhasevenbeenfoundbetweenthenumberofDNA adductsandthenumberofcigarettessmoked
[20] .ASwedishstudyhasnowshownthat
heavysmokerswithaGSTT1-positivegenotypehaveathreefoldincreasedriskforlung cancerwith23pack-yearsofsmokingOR2.6[1.3–5.0],whereastheriskisincreased
ninefoldOR9.3[1.9–46.3insmokerswiththeGSTT1-nullgenotype [114]
,agenuinerisk constellation.SimilarassociationshavealsobeenreportedwithN-acetyltransferaseNAT2
genotypeasPMs,particularlywhencombinedwiththeGSTM1-nullgenotype [115]
. Thesestudiesindicatethatthehighest-riskcombinationforincreasedsusceptibilityto
lungcanceristheCYP1A1genotypeplusaGSTM1defectbecauseofthefollowing:
•
ItresultsinmoreB[a]PDEadducts [112,114–116]
•
Approximately100-foldhigherB[a]PDE-DNAlevelsoccurthanwithanactiveformof GSTM1
[112] CarriersofhomozygousCYP1A1m1havehigherBPDE-DNAadductlevelsthancarriers
ofwildtypeCYP1A1 [114]
.Thus,whatevertheirethnicorigin,carriersofthehomozy- gousCYP1A1GSTM100traitareatincreasedriskfortobacco-inducedcancerofthe
lungs,headandneck.